Zachary A. Weber
A5047817306- Vaccine Coverage and Hesitancy
- SARS-CoV-2 and COVID-19 Research
- Influenza Virus Research Studies
- Respiratory viral infections research
- COVID-19 Clinical Research Studies
- COVID-19 epidemiological studies
- Viral gastroenteritis research and epidemiology
- Child and Adolescent Psychosocial and Emotional Development
- Injury Epidemiology and Prevention
- Bacterial Infections and Vaccines
- Maternal Mental Health During Pregnancy and Postpartum
- Family and Disability Support Research
- Birth, Development, and Health
- COVID-19 Pandemic Impacts
- Child Nutrition and Feeding Issues
- Viral Infections and Outbreaks Research
- Traumatic Brain Injury Research
- Obesity, Physical Activity, Diet
- Inclusion and Disability in Education and Sport
Westat (United States)
2022-2024
Kaiser Permanente
2022-2024
Baylor Scott & White Health
2022-2024
Intermountain Healthcare
2022-2024
Atrium Health Wake Forest Baptist
2024
Jewish Hospital
2024
Barnes-Jewish Hospital
2024
University of Arizona
2024
Cincinnati Children's Hospital Medical Center
2024
Seattle Children's Hospital
2024
During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of sequenced viral genomes in United States, with further diversification through November 2022.* Bivalent mRNA vaccines contain an ancestral strain component plus updated BA.4/BA.5 sublineages. On September 1, a single bivalent booster dose was recommended adults who had completed primary vaccination series (with or without subsequent doses), last administered ≥2 months earlier (1). 13-November 18, VISION...
Persons with moderate-to-severe immunocompromising conditions might have reduced protection after COVID-19 vaccination, compared persons without (1-3). On August 13, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended that adults receive an expanded primary series of 3 doses mRNA vaccine. ACIP followed recommendations September 23, for a fourth (booster) dose and 1, 2022, new bivalent vaccine booster dose, containing components BA.4 BA.5 sublineages Omicron (B.1.1.529)...
On September 1, 2022, CDC's Advisory Committee on Immunization Practices (ACIP) recommended a single bivalent mRNA COVID-19 booster dose for persons aged ≥12 years who had completed at least monovalent primary series. Early vaccine effectiveness (VE) estimates among adults ≥18 showed receipt of provided additional protection against COVID-19-associated emergency department and urgent care visits hospitalizations compared with that in received only doses (1); however, insufficient time...
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5)COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease.However, few estimates of vaccine effectiveness (VE) against medically attended illness are available.This analysis evaluated VE an COVID-19 dose COVID-19-associated emergency department (ED) or urgent care (UC) encounters and hospitalization among immunocompetent adults ≥18...
In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months.Using data from four vaccine effectiveness (VE) networks during 2023-24 season, interim VE was estimated among patients months with acute respiratory illness-associated medical encounters using a test-negative casecontrol study design.Among children and adolescents 6 months-17 years, against influenza-associated outpatient visits ranged 59% to 67% hospitalization 52% 61%.Among adults ≥18 33% 49%...
During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of sequenced viral genomes in United States, with further diversification through November 2022.* Bivalent mRNA vaccines contain an ancestral strain component plus updated BA.4/BA.5 sublineages. On September 1, a single bivalent booster dose was recommended adults who had completed primary vaccination series (with or without subsequent doses), last administered ≥2 months earlier (1). 13-November 18, VISION...
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. As with past vaccines, additional doses may be considered immunocompromising conditions, who are at higher risk and might have decreased response vaccination. this analysis, vaccine effectiveness (VE) of an dose against COVID-19-associated hospitalization was evaluated during...
On June 19, 2022, the original monovalent mRNA COVID-19 vaccines were approved as a primary series for children aged 6 months-4 years (Pfizer-BioNTech) and months-5 (Moderna) based on safety, immunobridging, limited efficacy data from clinical trials. December 9, CDC expanded recommendations use of updated bivalent to ≥6 months. vaccine effectiveness (VE) against emergency department or urgent care (ED/UC) encounters was evaluated within VISION Network during July 4, 2022-June 17, 2023,...
Abstract Background Following historically low influenza activity during the 2020–2021 season, United States saw an increase in circulating 2021–2022 season. Most viruses belonged to A(H3N2) 3C.2a1b 2a.2 subclade. Methods We conducted a test-negative case-control analysis among adults ≥18 years of age at 3 sites within VISION Network. Encounters included emergency department/urgent care (ED/UC) visits or hospitalizations with ≥1 acute respiratory illness (ARI) discharge diagnosis codes and...
Coronavirus disease 2019 (COVID-19) vaccination coverage remains lower in communities with higher social vulnerability. Factors such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure risk and access to healthcare are often correlated vulnerability may therefore contribute a relationship between observed vaccine effectiveness (VE). Understanding whether these factors impact VE could our understanding of real-world VE.
Abstract Background The 2022–2023 United States influenza season had unusually early activity with high hospitalization rates. Vaccine-matched A(H3N2) viruses predominated, lower levels of A(H1N1)pdm09 also observed. Methods Using the test-negative design, we evaluated vaccine effectiveness (VE) during against A–associated emergency department/urgent care (ED/UC) visits and hospitalizations from October 2022 to March 2023 among adults (aged ≥18 years) acute respiratory illness (ARI). VE was...
Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits and hospitalizations from four VE networks during 2024-25 season (October 2024-February 2025). Among children adolescents <18 years, against any 32%, 59%, 60% setting three networks, influenza-associated hospitalization 63% 78% two networks. adults ≥18 36% 54% 41% 55%...
Context : Collegiate athletes who are deaf or hard-of-hearing (D/HoH) diagnosed with concussions at a similar rate as hearing; however, little evidence exists on knowledge and attitudes of D/HoH toward concussions. This study aimed to examine differences in between hearing. Design Cross-sectional research design. Methods Of the 310 430 hearing that were invited participate, 90 D/HoH, 72 completed survey. The Rosenbaum Concussion Knowledge Attitudes Survey was used quantify attitude consists...
During the 2022-2023 influenza season, United States experienced highest influenza-associated pediatric hospitalization rate since 2010-2011. Influenza A/H3N2 infections were predominant.
The 2023-2024 influenza season had predominant A(H1N1)pdm09 virus activity, but A(H3N2) and B viruses co-circulated. Seasonal vaccine strains were well-matched to these viruses.
ABSTRACT Background Although psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID‐19 vaccine effectiveness (VE). This study evaluated risk of hospitalization and estimated mRNA VE stratified by disorder status. Methods In a retrospective cohort analysis the VISION Network in four US states, rate laboratory‐confirmed COVID‐19‐associated between December 2021 August 2022 was compared across diagnoses...
Parenting stress is associated with less optimal outcomes for children. Risk factors contributing to parenting in healthy toddlers have received little empirical attention. This study sought determine the that are parents of 18-month-old children.We analysed cross-sectional survey data from a prospective cohort focused on parent-child mealtime interactions. Families an child were recruited Columbus, Ohio, USA, between December 2017 and May 2019. Adjusted stepwise linear regression models...
Objective The accumulation of adverse events in childhood is linked to obesity, although the short‐term (1 2 years) dynamics weight change during life has not been investigated. Methods In Eunice Kennedy Shriver National Institute Child Health and Human Development Study Early Care Youth Development, mothers reported past year when their children were 54 months, 9 years, 11 years old. Children's height measured, BMI‐for‐age z scores calculated at 36 months 7, 9, 10, years. estimated 1‐...
ABSTRACT Background Immunocompromised (IC) persons are at increased risk for severe COVID-19 outcomes and less protected by 1-2 vaccine doses than immunocompetent (non-IC) persons. We compared effectiveness (VE) against medically attended of 2-3 mRNA viral-vector between IC non-IC adults. Methods Using a test-negative design among eight VISION Network sites, VE laboratory-confirmed COVID-19–associated emergency department (ED) or urgent care (UC) events hospitalizations from 26 August-25...